发明名称 INDUCTION OF THYROID IODIDE-HANDLING GENE EXPRESSION IN HUMAN CANCERS
摘要 Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0/G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium/iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes. Targeting major signaling pathways, such as the MAP kinase and PI3K/Akt pathways, for potent cell death, optionally coupled with induction of thyroid gene expression for adjunct radioiodine ablation therapy may be used for many human cancers, both thyroid and non-thyroid.
申请公布号 US2017014441(A1) 申请公布日期 2017.01.19
申请号 US201615002457 申请日期 2016.01.21
申请人 THE JOHNS HOPKINS UNIVERSITY 发明人 Xing Michael Mingzhao
分类号 A61K31/713;C12N15/113;A61K31/428;A61K51/00;A61K31/277 主分类号 A61K31/713
代理机构 代理人
主权项 1. A method of treating a human cancer in a patient comprising: administering an inhibitor of a PI3K/Akt pathway protein or its expression to the patient; and administering an inhibitor of a MAP kinase pathway protein or its expression to the patient, wherein the inhibitors are administered in sufficient amounts to induce expression of one or more iodide-handling genes in the human cancer.
地址 Baltimore MD US